Phase 3 N=135 The Effect Of Oral Ibandronate In Male Osteoporosis
Male Osteoporosis
Primary: Mean Percent Change in BMD of the Lumbar Spine From Baseline to Month 12 — .94; 3.52 percent — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=242 Study to Compare the Efficacy and Safety of DenosumAb Versus Placebo in Males With Osteoporosis
Low Bone Mass · Low Bone Mineral Density · Males With Osteoporosis
Primary: Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12 — 0.9; 5.7 Percent — p=<0.0001
N/A N=3,512 Models of Primary Osteoporosis Screening in Male Veterans
Osteoporosis · Osteopenia · Osteoporotic Fracture
Primary: Proportion of Participants Screened for Osteoporosis — 830; 33 participants
Phase 1 N=19 Melatonin Osteoporosis Prevention Study
Osteoporosis · Osteopenia
Primary: The Effect of Melatonin (3 mg) or Placebo on the Mean Change in Serum Osteocalcin (OC) Levels in Women After 6 Months, as Compared to Baseline — -0.6; 1.83 ng/mL
Phase 3 N=31 Combination Risedronate - Parathyroid Hormone Trial in Male Osteoporosis
Osteoporosis
Primary: Change in Spine Bone Density — 6.95; 3.76; 5.68 % change in LS BMD
Phase 3 N=1,199 Efficacy in Reducing Fractures and Safety of Zoledronic Acid in Men With Osteoporosis
Male Osteoporosis
Primary: Percentage of Participants With at Least One New Morphometric Vertebral Fracture Over 24 Months — 1.6; 4.9 Percentage of Participants
Phase 4 N=6 Bone Histomorphometry in Postmenopausal Men and Women With Osteoarthritis Undergoing Total Hip Replacement
Osteoporosis
Primary: Percentage of Participants With Modeling Based Bone Formation in the Femoral Neck — 100 percentage of participants
N/A N=18 Enhancing Skeletal Adaptations to PTH and Exercise
Exercise · Bone Resorption · Bone Formation
Primary: Change in C-terminal Peptide of Type 1 Collagen (CTX) — 0.03; 0.03; 0.05; 0.03 ng/mL
Phase 4 N=50 Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
Prostate Cancer
Primary: Percent Change in Bone Mineral Density — 0.1; -2; 0.2; -2.2 Percent Change — p=0.004
Phase 3 N=285 Efficacy and Safety of Risedronate Therapy Administered 35 mg Once A Week in Men With Osteoporosis
Other Osteoporosis
Primary: Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD), 24 Months/Endpoint, ITT Population. — 1.22; 5.75 Percent Change — p=<0.0001
Phase 3 N=276 Heartland Osteoporosis Prevention Study
Osteopenia
Primary: Change in Bone Strength Index of the Distal Tibia Based on Randomization to Control, Risedronate, or Exercise Group. — 2098.7; 1993.3; 2001; 2105.89 mg^2/mm^4 — p=0.7
Phase 3 N=77 Bone Loss in Women With Anorexia Nervosa
Anorexia Nervosa
Primary: Bone Mineral Density — 3.2; -0.6 percent change — p=<0.0001
Phase 2 N=80 Parathyroid Hormone (PTH) for Osteoporosis in Postmenopausal Women
Postmenopausal Osteoporosis · Osteoporosis
Primary: Changes in Indices of Bone Turnover — 4418; 3696; 956; 822 months*(ng/ml - baseline ng/ml)
Phase 3 N=29 Secondary Prevention of Osteoporosis
Osteoporosis
Primary: Number Adherent With the Intervention — 29 participants
Phase 4 N=92 Testosterone Therapy and Bone Quality in Men With Diabetes and Hypogonadism
Type 2 Diabetes Mellitus · Hypogonadism
Primary: Finite Element Analysis of Bone to Measure Bone Strength — 1.2; 1.6; 1.6; 0.88 % change — p=<0.05
Phase 2 N=10 Healthy Body, Healthy Bones After Bariatric Surgery Trial
Bariatric Surgery Candidate · Bone Loss · Bone Resorption
Primary: Change in Hip Bone Mineral Density (BMD) — 0; -.03 g/cm2
Phase 3 N=22 Forteo for the Treatment of Unexplained Osteoporosis in Premenopausal Women
Menopause · Fracture · Osteoporosis
Primary: Change in Lumbar Spine Bone Density by Dual Energy X-ray Absorptiometry (DXA) — 10.8 percentage of BMD change
Phase 2 N=399 A Study to Examine the Effects of an Experimental Drug on Postmenopausal Osteoporosis (MK-0822-004)
Osteoporosis
Primary: Percentage Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at 12 Months — -0.13; -0.62; 1.50; 2.65 Percentage change — p=<=0.001
Phase 2 N=35 Testosterone and Growth Hormone for Bone Loss in Men
Hypopituitarism · Hypogonadism · Growth Hormone Deficiency
Primary: MicroMRI-derived Structural (Bone Volume Fraction-BVF) of the Distal Tibia at Baseline and After One and Two Years of Treatment. — 0.112; 0.104; 0.119; 0.111 unitless
N/A N=19 Role of T-cells in Post-Menopausal Osteoporosis
Osteoporosis
Primary: Changes in T-cell Activation Measured by Flow Cytometry, Specifically the Percentage of CD3+CD69+ T-cells — 3.6; 1.8 percentage of CD3 positive cells
Phase 3 N=92 Comparison of the Effects of 2 Drugs on Lumbar Spine Volumetric BMD in Men With Glucocorticoid-Induced Osteoporosis
Osteoporosis
Primary: Change From Baseline in Lumbar Spine Volumetric Trabecular Bone Mineral Density (BMD) by Quantitative Computerized Tomography (QCT) at 18 Months — 12.28; 2.94 milligram…
Phase 3 N=224 Zoledronic Acid in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia, 45 Years of Age and Older
Osteopenia
Primary: Percentage Change in Lumbar Spine Bone Mineral Density (BMD) at Month 24 Relative to Baseline, by Stratum — 4.62; 4.03; -2.24; 5.60 Percentage change in BMD
N/A N=33 Effects of Physical Training on Bone Turnover and Quality of Life in Osteopenic Postmenopausal Women.
Osteopenia · Bone Turnover Markers · Quality of Life
Primary: Variation in Serum Levels of Procollagen 1 N-terminal Peptide (P1NP) — 58.34; 57.91 mcg/L — p=0.05
Phase 3 N=228 Safety and Efficacy of Abaloparatide-SC in Men With Osteoporosis (ATOM)
Osteoporosis · Osteoporosis, Age-Related · Osteoporosis Localized to Spine
Primary: Percent Change From Baseline in Lumbar Spine BMD at Month 12 — 8.4820; 1.1654 percent change — p=<0.0001
N/A N=1,100 A 5-Year Follow-up Study Investigating Factors Associated With Osteoporotic Fracture in Chinese Postmenopausal Women
Osteoporotic Fractures · Osteoporosis, Postmenopausal
Primary: Non-vertebral Fracture Incidence — 70; 0 participants
Phase 3 N=16 Prospective Biomarkers of Bone Metabolism in Hemophilia A
Hemophilia · Bone Disease
Primary: Bone Biomarker Density (BMD) — -0.74; -0.16; -0.16 Z-Score
Phase 4 N=20 Effect of Atorvastatin on Bone-vascular Axis
Osteoporosis · Hypercholesterolemia
Primary: Relative Change in OPG/RANK/RANKL mRNA Expression in Isolated T Cells and Monocytes — 0.76 relative fold change — p=<0.05
Phase 4 N=53 Alendronate Prevents Microarchitectural Deterioration of Trabecular Bone in Early Postmenopausal Women
Osteopenia · Osteoporosis
Primary: Mean % Change From Baseline in Trabecular Number (Tb.N) by HR-pQCT — 2.1; -0.6; 0.9; 4.1 Percent change
Phase 2 N=208 The Effect of Protein Supplementation on Bone Health in Healthy Older Men and Women
Bone Resorption · Osteoporosis
Primary: Change in Anterior-posterior Spine Bone Mass Density Measured by Dual Energy X-ray Absorptiometry (DXA) Compared to Baseline — 0.51; 0.51 percentage change
Phase 4 N=33 µMRI of Therapeutic Intervention in Postmenopausal Osteoporosis
Osteoporosis, Osteopenia
Primary: Percentage of Change in Trabecular Surface-to-curve Ratio — 9.1; 7.1 Percentage of Change